Clinical outcome measures in multiple sclerosis: A review

Autoimmunity Reviews, Год журнала: 2020, Номер 19(5), С. 102512 - 102512

Опубликована: Март 12, 2020

Язык: Английский

---

Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis

Journal of Neurology, Год журнала: 2019, Номер 267(12), С. 3489 - 3498

Опубликована: Май 25, 2019

Язык: Английский

---

Identifying Progression in Multiple Sclerosis: New Perspectives

Annals of Neurology, Год журнала: 2020, Номер 88(3), С. 438 - 452

Опубликована: Июнь 7, 2020

The identification of progression in multiple sclerosis is typically retrospective. Given the profound burden progressive sclerosis, and recent development effective treatments for these patients, there a need to establish measures capable identifying early disease course. Starting from pathological findings, this review assesses state art potential able predict sclerosis. Future promising biomarkers that might shed light on mechanisms are also discussed. Finally, expansion concept by including an assessment cognition, patient-reported outcomes, comorbidities, considered. ANN NEUROL 2020;88:438-452.

Язык: Английский

---

Treatment effects of cladribine tablets on data-driven patterns of regional grey matter atrophy in multiple sclerosis

Multiple Sclerosis Journal, Год журнала: 2025, Номер unknown

Опубликована: Фев. 25, 2025

Background: Treatment with cladribine tablets (CladT) in relapsing–remitting multiple sclerosis (RRMS) reduced global grey matter (GM) atrophy, but the effects on regional GM are unknown. Objectives: This study aimed to investigate effect of CladT compared placebo magnetic resonance imaging (MRI)-derived patterns atrophy. Methods: We used MRI and clinical data from CLARITY study, including 393 people RRMS (CladT (3.5 mg/kg), n = 200 or placebo, 193) at baseline, 24, 48 96 weeks after treatment initiation. SynthSeg-derived volume changes atrophy derived source-based morphometry were analysed for group differences over time associations disability using mixed-effect models. Results: Deep (β −0.03, p < 0.01), thalamus −0.04, 0.01) brainstem–thalamus pattern 0.05) showed higher reduction treated group. These regions no during a predefined pseudo-atrophy period, where loss was worse Between W24 W96, Expanded Disability Status Scale (EDSS) scores associated lower deep −0.16, 0.001), thalamic −0.12, 0.05). Conclusion: clinically relevant slower neurodegeneration RRMS. Strongest seen GM, thalamus, brainstem, underlining importance measures assessing effects.

Язык: Английский

---

Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials

Neurology, Год журнала: 2025, Номер 104(10)

Опубликована: Апрель 21, 2025

Sensitive and meaningful disability worsening measures remain an unmet medical need in multiple sclerosis (MS). Composite confirmed worsening/progression (cCDW/cCDP) combines the Expanded Disability Status Scale (EDSS) with performance tests of ambulation dexterity (Timed 25-Foot Walk Test [T25FWT] Nine-Hole Peg [9HPT]). We assessed relation changes these to understand utility cCDW/cCDP as endpoint for MS trials. Clinical trials measuring all components cCDW were selected analysis (i) individual patient-level data from Roche-sponsored studies characterize association between performance-test subsequent EDSS (ii) population-level published reporting treatment effects on either cCDP or T25FWT 9HPT events examine relationship events. Analysis (i): 6 Phase III comprising 4,979 patients relapsing-remitting (RRMS; n = 1,225), relapsing (RMS; 1,656), progressive (PMS; 922), primary (PPMS; 1,171), a cutoff November 2022, included patient analyses. For trials, associated increased risk (hazard ratios [HRs], p values: 2.11-5.20, 0.07-<0.001); similar associations found HRs later ranging 1.47 2.66 (p values 0.24-<0.001). without first 96 study weeks, weeks (HRs, 1.74-3.26, 0.01-<0.001; 1.45-3.08, 0.45-<0.001). Patients more likely experience ≥8-point change baseline at final visit 29-item Multiple Sclerosis Impact physical subscale (risk ratios, 1.45-2.17, 0.004-<0.001; 1.26-1.87, 0.15-0.03). (ii): In 9 included, predictive (Spearman correlation [95% CI] 0.82 [0.34-0.96], 0.005). this post hoc analysis, was harbinger correlated those EDSS. These results establish validity clinical relevance worsening, thus supporting use outcome progression ClinicalTrials.gov Identifiers: NCT01247324 (OPERA I); submitted 23, 2010; enrolled: August 31, 2011; available clinicaltrials.gov/study/NCT01247324. NCT01412333 II); 8, September 20, clinicaltrials.gov/study/NCT01412333. NCT03085810 (ENSEMBLE); March 16, 2017; 27, clinicaltrials.gov/study/NCT03085810. NCT01194570 (ORATORIO); 28, 3, clinicaltrials.gov/study/NCT01194570. NCT03523858 (CONSONANCE); April 2018; May clinicaltrials.gov/study/NCT03523858. NCT00087529 (OLYMPUS); July 9, 2004; clinicaltrials.gov/study/NCT00087529.

Язык: Английский

---

Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis

Multiple Sclerosis Journal, Год журнала: 2020, Номер 27(9), С. 1421 - 1431

Опубликована: Ноя. 5, 2020

Background: Clinical measures in multiple sclerosis (MS) face limitations that may be overcome by utilising smartphone keyboard interactions acquired continuously and remotely during regular typing. Objective: The aim of this study was to determine the reliability validity keystroke dynamics assess clinical aspects MS. Methods: In total, 102 MS patients 24 controls were included observational study. Keyboard obtained with Neurokeys app. Eight timing-related features assessed for intraclass correlation coefficients (ICCs); construct analysing group differences (in fatigue, gadolinium-enhancing lesions on magnetic resonance imaging (MRI), vs controls); concurrent correlating disability measures. Results: Reliability moderate two (ICC = 0.601 0.742) good excellent remaining six 0.760–0.965). Patients had significantly higher latencies than controls. Latency between key presses correlated highest Expanded Disability Status Scale ( r 0.407) latency releases Nine-Hole Peg Test Symbol Digit Modalities (ρ 0.503 −0.553, respectively), ps < 0.001. Conclusion: Keystroke reliable, distinguished controls, associated Consequently, are a promising valid surrogate marker

Язык: Английский

---

Ocrelizumab for multiple sclerosis

Cochrane library, Год журнала: 2022, Номер 2022(5)

Опубликована: Май 18, 2022

Язык: Английский

---

MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis

Neuroradiology, Год журнала: 2019, Номер 61(2), С. 155 - 162

Опубликована: Янв. 8, 2019

Язык: Английский

---

Differentiating societal costs of disability worsening in multiple sclerosis

Journal of Neurology, Год журнала: 2019, Номер 267(4), С. 1035 - 1042

Опубликована: Дек. 17, 2019

Язык: Английский

---

Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?

Multiple Sclerosis Journal, Год журнала: 2019, Номер 26(11), С. 1381 - 1391

Опубликована: Авг. 2, 2019

The objective of the study was to determine whether early infratentorial and/or spinal cord lesions are long-term cumulative predictors disability progression in multiple sclerosis (MS).We selected 153 MS patients from longitudinal Amsterdam cohort. Lesion analysis performed at baseline and year 2. Disability after 6 11 years measured using Expanded Status Scale (EDSS) EDSS-plus (including 25-foot walk 9-hole peg test). Patients with or were compared for risk 6- 11-year without lesions, respectively. Subsequently, on both locations only lesions.Baseline show a higher 6-year EDSS (odds ratio (OR): 3.6, p = 0.007) (OR: 2.5, 0.028) 2.8, 0.047). did not have than lesions.The presence seems be dominant factor progression. Simultaneous undisputedly predict

Язык: Английский

---